(PRWEB) February 18, 2013
As new developments advance the multidistrict litigation* involving allegations that the popular blood thinner Pradaxa allegedly caused severe internal bleeding Resource4thePeople announced that it is now providing links to lawyers offering such victims free consultations.
The announcement comes as a federal judge who has been assigned to oversee pre-trial evidence-gathering and other proceedings in the case has issued a ruling that grants victims’ lawyers access to details involved in the settlement of a whistleblower suit.
U.S. District Court Judge David R. Herndon granted the request to victims’ lawyers in the multidistrict litigation* seeking access to a case settled by Pradaxa manufacturer Boehringer Ingelheim last year.
“Because this litigation against Pradaxa over allegations of internal bleeding side effects has been designated by the federal court system as a multidistrict litigation and the case is advancing toward trial stage there have been inquiries from consumers confused about their legal options,” said Resource4thePeople.
“Therefore, we are announcing new links to provide any consumer wishing to determine what their legal status might be in this litigation referrals to legal experts who are completely versed in determining the eligibility to seek compensation.”
Resource4thePeople also is attempting to clarify any questions about whether the opportunity to join in this litigation remains possible by pointing out that the judge in the case has not issued any order blocking new lawsuits and that additional cases have continued to be added as the litigation has advanced.
Resource4thePeople also is announcing that there is now a link available to consumers seeking updates about litigation, medical research findings and reports from the Food and Drug Administration on the organization’s web site at: http://www.resource4thepeople.com/defectivedrugs/pradaxa-lawsuits.html
Judge Herndon’s ruling* against Boehringer Ingelheim involved a $95 million settlement over the company’s marketing campaign to promote Pradaxa.
The current litigation before Herndon was assigned to him by a federal judicial panel which grouped together similar lawsuits against the company which all claim that Pradaxa can cause serious internal bleeding problems which can lead to heart attacks and brain hemorrhages.*
In another ruling, Herndon has scheduled the first bellwether trials in the Pradaxa litigation to start in August, 2014.* In multidistrict litigations, bellwether trials are scheduled by judges to provide both sides the opportunity to test the strengths and weaknesses of their cases by choosing certain cases approved by both sides for trial.
Although the Pradaxa cases before Herndon are seeking class-action status the judge will not make that decision until after the bellwether trials, according to the court docket in the litigation.
Boehringer Ingelheim has denied the claims that have been filed against them in the Pradaxa litigation, including allegations that the company was negligent by failing to adequately warn health care professionals and patients about bleeding side effects.*
According to allegations in the Pradaxa multi-district litigation, the drug was approved by the FDA in 2010 as an improvement over another blood-thinner, warfarin, for patients vulnerable to atrial fibrillation.
Plaintiffs in the Pradaxa multi-district litigation are claiming that in cases of internal bleeding there is an antidote for warfarin but there is no antidote for Pradaxa and that in some cases deaths have occurred.
There are currently over 150 lawsuits in the multi-district litigation before Judge Herndon and Bloomberg News recently reported that Pradaxa “has been linked to more than 500 U.S. deaths over a two-year period.”**
Bloomberg also reported that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribing it. FDA officials said they received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.”**
Resource4thePeople also is advising consumers who may have been or are being treated with Pradaxa that the FDA recently issued a Drug Safety Communication warning that the medication should not be used in patients with mechanical prosthetic heart valves.***
In the communication the FDA also noted a previously released Drug Safety Communication about the risk of serious bleeding associated with the use of Pradaxa in patients with non-valvular atrial fibrillation, the population for which the drug is approved.